• Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Internal Medicine, Mayo Clinic, Rochestor, MN
• World-renowned expert in treating patients with Primary Amyloidosis

• Professor of Neurology and Biomedical Engineering, Oregon Health Sciences University
• Director of the Layton Aging and Alzheimer's Disease Center
• Director of the Oregon Center for Aging Technology

• Founder, CEO and Scientific Director of the Parkinson's Institute
• Former Chairman of the Department of Neurology for the Santa Clara Valley Medical Center in San Jose, CA

• Professor of Neurosciences and Pathology, University of California, San Diego
• Director of Autopsy Service, Department of Pathology, University of California, San Diego

• Professor and Vice Chairman, Department of Psychiatry and Behavioral Sciences at University of Washington
• Director, University of Washington Alzheimer's Disease Research Center
• Executive Director, Mental Health Service, VA Puget Sound Health Care System

• Former Associate Vice President and Group Director, Chemistry Research, Hoffmann-La Roche
• Co-founder of Ariad Pharmaceuticals, Cambridge, MA

• Professor, Department of Pharmacology and Neurology, Boston University School of Medicine.

Alan D. Snow, Ph.D. - Chairman, President, and Chief Scientific Officer: Dr. Snow is the Founder and Chairman of the Company's Board of Directors. He previously served as a Research Associate Professor of Pathology at the University of Washington, and is a world-recognized authority on the role of proteoglycans in Alzheimer's and amyloid diseases. He holds a B.S. in Biology/Chemistry from Bowling Green State University in Ohio, an M.S. in Anatomy from University of Western Ontario (London, Ontario, Canada), and a Ph.D. in Pathology from Queen's University (Kingston, Ontario, Canada). At Queen's University, Dr. Snow worked in the laboratory of Dr. Robert Kisilevsky, one of the founders of Neurochem Inc. Dr. Snow's thesis work led to new discoveries concerning the pathogenic role that proteoglycans and glycosaminoglycans play in amyloid diseases.

At the University of Washington, Dr. Snow was the first to identify and demonstrate specific proteoglycans in amyloid deposits in Alzheimer's disease. Dr. Snow also co-authored a number of papers with Nobel laureate Dr. Stanley Prusiner and was the first to identify specific proteoglycans in the brain amyloid deposits in a variety of prion diseases. Dr. Snow is the author of more than 50 scientific publications and has presented his research on amyloid disease and proteoglycans at over 120 scientific meetings.

Dr. Snow founded ProteoTech in 1996, then left the University of Washington in 1999 to serve as the Company's Chairman, President, acting CEO and CSO. He was instrumental in personally writing and acquiring over $10 million in grant funding from the NIH SBIR and The Michael J. Fox Foundation for Parkinson's research LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) program. He helped hire corporate and patent lawyers, as well as regulatory and scientific advisors, and recruited world-class research scientists and key management and consultant positions for the Company. He helped negotiate and write/edit business contracts and agreements for various contract research organizations and university collaborations, and guided major drug development programs for ProteoTech in Alzheimer's, Parkinson's, type 2 diabetes and systemic amyloidosis. He helped write and guided patent lawyers and patent agents on more than 165 patents pertaining to new therapeutics and diagnostics platform for amyloid diseases and proteoglycan technologies.

Steve Runnels, MBA - Chief Executive Officer: Mr. Steve Runnels has more than twenty-six years of successful and proven international business management experience in the healthcare industry. He has held the position of President and CEO of several start-up biopharmaceutical companies, executive vice president and Board member of publicly traded NeoTherapeutics, Inc. (NEOT: NASDAQ) and Vice President of Marketing and Business Development at Sigma-Aldrich, a Fortune 500 company.

He has led drug discovery and in vitro diagnostic product development activities in the therapeutic areas of Central Nervous System, Oncology, Clinical Cytogenetics, Assisted Reproductive Technologies, Immunohematology and Diseases of Bone and Cartilage.

Mr. Runnels is a Senior Industry Advisor for the National Institutes of Health Commercialization Program (NIH-CAP) managed by the Los Angeles Regional Technology Association (LARTA). He is on the Advisory Board for Extension Courses in Medical Product Development, at the University of California – Irvine and is on the Board of Directors at Biosome, Inc. Mr. Runnels holds a B.S. in Cell Biology and certification from the American Society of Clinical Pathology as a specialist in Immunohematology. He has an MBA in International Business and is a Ph.D. candidate in Management.

Dennis McCurley, MBA - Chief Operations Officer and Chief Financial Officer: Mr. McCurley is responsible for the Company's daily operations. Since joining the Company in 1997, Mr. McCurley has functioned as a key member of the Senior Management Team. Over the past 25 years, prior to joining ProteoTech, Mr. McCurley has held various senior management positions with other companies including VP-Franchising, VP-Regional Manager with First Interstate Bancorp, VP-District Manager with Wells Fargo Bank and CEO of Capital Access One. Mr. McCurley has also participated in establishing and growing several innovative companies before joining ProteoTech.

Mr. McCurley earned his M.B.A. from the University of Southern California in Finance and is a PhD candidate in Management and Organizational Behavior. Mr. McCurley is very involved in the community, having served on several nonprofit boards.

No bio at this time